glp 1 agonist schizophrenia GLP-1 semaglutide reduced diabetes risk (HbA1c) and weight (20 lb) in new RCT of people with #schizophrenia, prediabetes, and obesity: GLP-1 Receptor Agonists in Mood

reliable e-wallets and cards speed up withdrawals

The starting dose period is an excellent time to establish baseline measurements for blood glucose, liver function, and lipid panels

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

The helix-forming propensity of d-alanine in a right-handed -helix

Staying well hydrated is a simple way to help support proper kidney function

Brinkhaus, M